INTERFERON EPSILON (IFNE1) AS A MARKER FOR TARGETED CANCER THERAPY

摘要

Disclosed is a method of employing Interferon Epsilon (IFNEI) as a therapeutic response, prognostic, or pharmacodynamic marker for cancer chemotherapeutic treatment using cyclin dependent kinase (CDK) inhibitors. IFNEI transcript is upregulated when cancer cells are treated with CDK inhibitors. The disclosure also includes the method of measuring a level of IFNE 1 or IFNE 1 mRNA in a subject's tumor, blood or other tissues. An increased level of IFNEI in comparison with a control level can be used as an indicator that the CDK inhibitor has produced a therapeutic effect or an indicator that a tumor is sensitive to a CDK inhibitor.